Fluoroquinolone Resistance and Pharmacokinetics

1. Mechanisms of Resistance

Frequency of emergence During fluoroquinolone therapy, resistant mutants emerge at a rate of about 1 in every 10^7-10^9 organisms, most notably among staphylococci, Pseudomonas aeruginosa, and Serratia marcescens. This is a fairly high spontaneous mutation frequency for such potent drugs, which is part of what makes fluoroquinolone resistance clinically important - Katzung's Basic and Clinical Pharmacology, 16th Ed.

A. Chromosomal (target-site) resistance - the classic and most common mechanism

One or more point mutations occur in the quinolone resistance-determining region (QRDR) of the target enzymes - DNA gyrase (gyrA/gyrB genes) and/or topoisomerase IV (parC/parE genes).
These mutations reduce drug binding affinity to the enzyme-DNA complex.
Decreased membrane permeability (porin changes) and increased efflux pump activity can also contribute, though efflux is a less potent and less common cause than target mutation - Lippincott Illustrated Reviews: Pharmacology; Harrison's Principles of Internal Medicine, 22nd Ed.
A single mutation usually gives low-level resistance; accumulation of multiple mutations in gyrA/parC (or both) produces high-level, clinically significant resistance.

This is illustrated well in the diagram from your slide 15:

Mechanism of fluoroquinolone resistance - mutation of binding sites and efflux pump

(showing mutation of the DNA-binding site as the dominant, more potent mechanism, and the efflux pump as a less potent/less common route)

B. Plasmid-mediated resistance - two types described more recently, and important because plasmids spread resistance horizontally between bacteria:

Qnr proteins - a family of proteins that bind to and physically protect DNA gyrase and topoisomerase IV from fluoroquinolone inhibition.
AAC(6')-Ib-cr - a variant of an aminoglycoside acetyltransferase enzyme that has acquired the ability to acetylate and inactivate ciprofloxacin (and norfloxacin) specifically, at the piperazinyl substituent.

Both plasmid mechanisms individually confer only low-level resistance, but they raise the minimum inhibitory concentration enough to allow the bacterium to survive drug exposure and go on to acquire the chromosomal point mutations that produce high-level resistance - essentially acting as a stepping stone.

Cross-resistance Because all fluoroquinolones target the same two enzymes (DNA gyrase and topoisomerase IV), high-level resistance to one fluoroquinolone generally confers cross-resistance to the entire class. This is why resistance testing with one agent (e.g., ciprofloxacin) is often used as a class marker.

2. Pharmacokinetics

Absorption: Well absorbed orally, with bioavailability of 80-95%. They distribute widely into body tissues and fluids (including prostate, lung, bone, and phagocytes).
Serum half-life: Ranges from 3 to 10 hours depending on the specific agent, which is why dosing intervals vary across the class (e.g., ciprofloxacin twice daily vs. levofloxacin/moxifloxacin once daily).
Drug interaction affecting absorption: Divalent and trivalent cations (Ca²⁺, Mg²⁺, Al³⁺, Fe²⁺/Fe³⁺, Zn²⁺) - found in antacids, dairy products, and mineral supplements - chelate fluoroquinolones in the gut and markedly impair absorption. Clinically, oral fluoroquinolones should be dosed 2 hours before or 4 hours after any cation-containing product.
Elimination: Most fluoroquinolones are cleared renally via a combination of tubular secretion and glomerular filtration.
Renal dose adjustment: Required in patients with creatinine clearance below 50 mL/min, since accumulation increases risk of toxicity (e.g., CNS effects, tendinopathy).

Quick clinical takeaway

The two resistance families work together: plasmid-borne Qnr proteins and AAC(6')-Ib-cr provide "background" low-level protection that lets bacteria survive long enough to accumulate the gyrA/parC point mutations that cause the high-level, cross-class resistance seen clinically. On the pharmacokinetics side, the biggest practical prescribing points are avoiding co-administration with polyvalent cations and adjusting the dose in renal impairment.

Note on current evidence: A recent (2025) systematic review and meta-analysis (PMID: 41053187) looked at global prevalence of fluoroquinolone-resistant Morganella morganii, and other 2024-2025 systematic reviews have tracked rising fluoroquinolone resistance in Salmonella and Brucella isolates. These don't change the basic mechanisms described above, but they confirm that plasmid-mediated and chromosomal resistance mechanisms are contributing to a measurable rise in resistance prevalence across multiple pathogens worldwide - reinforcing why judicious fluoroquinolone use and susceptibility testing remain important.

This is a shared conversation. Sign in to Orris to start your own chat.